Voretigene neparvovec (VN; AAV2-hRPE65v2) is the first approved ocular gene augmentation therapy in patients with visual impairments, due to biallelic RPE65 mutation-associated IRDs, who have sufficient viable retinal cells [9,10]. This evidence concerns the gene RPE65 and respiratory distress syndrome in premature infants.